Supplementary Online Content


**eTable 1.** Concomitant medication use during the treatment period

**eTable 2.** Discontinuation due to adverse events and biochemical abnormalities in patients treated with placebo and varespladib

This supplementary material has been provided by the authors to give readers additional information about their work.
eTable 1. Concomitant medication use during the treatment period

<table>
<thead>
<tr>
<th>Medication</th>
<th>Placebo (N=2573)</th>
<th>Varespladib (N=2572)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>2359 (91.7)</td>
<td>2340 (91.0)</td>
</tr>
<tr>
<td>Clopidogrel, ticlopidine, or prasugrel</td>
<td>2209 (85.9)</td>
<td>2169 (84.3)</td>
</tr>
<tr>
<td>β-Blocker</td>
<td>2061 (80.1)</td>
<td>2059 (80.1)</td>
</tr>
<tr>
<td>ACE inhibitor or ARB</td>
<td>1931 (75.0)</td>
<td>1929 (75.0)</td>
</tr>
</tbody>
</table>

Abbreviations. ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.
eTable 2. Discontinuation due to adverse events and biochemical abnormalities in patients treated with placebo and varespladib

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Placebo (n=2573)</th>
<th>Varespladib (n=2572)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discontinuation due to adverse events</td>
<td>36 (1.4)</td>
<td>72 (2.8)</td>
</tr>
<tr>
<td>ALT/AST &gt;3xULN</td>
<td>6 (0.2)</td>
<td>38 (1.5)</td>
</tr>
<tr>
<td>Total bilirubin &gt;2xULN</td>
<td>4 (0.2)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>CK &gt;3xULN</td>
<td>9 (0.5)</td>
<td>6 (0.3)</td>
</tr>
<tr>
<td>Creatinine &gt;ULN</td>
<td>84 (4.4)</td>
<td>64 (3.4)</td>
</tr>
</tbody>
</table>

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; CK, creatine kinase; ULN, upper limit of normal. Reported as number (percentage).